Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Metformin is the most widely prescribed oral treatment for diabetes, and the only one that showed a survival benefit.
Yet, there is no consensus on the optimal dose and withdrawal of metformin in chronic kidney disease (CKD) patients.
The aim of the study is to describe the use and side-effects of metformin in CKD patients in routine practice.
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| 6 groups, for each CKD stage (1, 2, 3a, 3b, 4, 5) | All patients with type 2 diabetes seen for the first time by a nephrologist. |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| modalities of metformin prescription | Other | Metformin prescription or not, in each CKD stage |
|
| Measure | Description | Time Frame |
|---|---|---|
| Percentage of patients receiving metformin | metformin use during chronic kidney disease. Percentage of patients receiving metformin will be recorded. | every January 1st up to 2020 |
| Measure | Description | Time Frame |
|---|---|---|
| Dose of metformin | metformin use during chronic kidney disease. Dose of metformin will be recorded. | every January 1st up to 2020 |
| Occurence of reasons for non-prescription of metformin | metformin use during chronic kidney disease. Occurence of reasons for non-prescription of metformin will be recorded. |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
All patients with type 2 diabetes seen by a nephrologist at the University hospital of Lyon Sud, between March 2014 and March 2020
| Name | Role | Phone | Extension | |
|---|---|---|---|---|
| Denis FOUQUE, MD PhD | Contact | (0)4 7267 8704 | +33 | denis.fouque@univ-lyon1.fr |
| Name | Affiliation | Role |
|---|---|---|
| Denis FOUQUE, MD PhD | Claude Bernard University, Lyon, France, Lyon Sud university hospital | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Claude Bernard University, Lyon, France, Lyon Sud university hospital | Recruiting | Pierre-Bénite | 69310 | France |
| PubMed Identifier | Type | Citation | Retractions |
|---|---|---|---|
| 30145030 | Derived | Coliche V, Koppe L, Laville M, Nouvier M, Pelletier S, Trolliet P, Fouque D. Metformin misuse in chronic kidney disease. Diabetes Metab. 2020 Sep;46(4):337-339. doi: 10.1016/j.diabet.2018.07.005. Epub 2018 Jul 24. No abstract available. |
Not provided
Not provided
Not provided
| ID | Term |
|---|---|
| D003924 | Diabetes Mellitus, Type 2 |
| D051436 | Renal Insufficiency, Chronic |
| D000140 | Acidosis, Lactic |
| ID | Term |
|---|---|
| D003920 | Diabetes Mellitus |
| D044882 | Glucose Metabolism Disorders |
| D008659 | Metabolic Diseases |
| D009750 | Nutritional and Metabolic Diseases |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| every January 1st up to 2020 |
| CKD stages | CKD stages will be recorded. | every January 1st up to 2020 |
| Doses of oral antidiabetes medications | Oral antidiabetic medications use during chronic kidney disease. Doses of oral antidiabetes medications (sulfonylureas, alpha-glucosidase inhibitors, Dipeptidyl peptidase-4 (DPP4) inhibitors, incretin mimetics, SGLT2 inhibitors) will be recorded. | every January 1st up to 2020 |
| starting time of insulin | need for insulin | every January 1st up to 2020 |
| occurrence of lactic acidosis | data file analysis and record of lactic acidosis episodes | every January 1st up to 2020 |
| D004700 | Endocrine System Diseases |
| D051437 | Renal Insufficiency |
| D007674 | Kidney Diseases |
| D014570 | Urologic Diseases |
| D052776 | Female Urogenital Diseases |
| D005261 | Female Urogenital Diseases and Pregnancy Complications |
| D000091642 | Urogenital Diseases |
| D052801 | Male Urogenital Diseases |
| D002908 | Chronic Disease |
| D020969 | Disease Attributes |
| D010335 | Pathologic Processes |
| D013568 | Pathological Conditions, Signs and Symptoms |
| D000138 | Acidosis |
| D000137 | Acid-Base Imbalance |